When we talk about the cost of AI infrastructure, the focus is usually on Nvidia and GPUs -- but memory is an increasingly ...

Henry Yuen is developing a new mathematical language to describe problems whose inputs and outputs aren’t ordinary numbers.

Lance Fortnow on the current status and future outlook of solving the P-NP problem.

While the creation of this new entity marks a big step toward avoiding a U.S. ban, as well as easing trade and tech-related tensions between Washington and Beijing, there is still uncertainty ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

As the world races to build artificial superintelligence, one maverick bioengineer is testing how much unprogrammed intelligence may already be lurking in our simplest algorithms to determine whether ...

When Edsger W. Dijkstra published his algorithm in 1959, computer networks were barely a thing. The algorithm in question found the shortest path between any two nodes on a graph, with a variant ...

Recursion Pharmaceuticals (RXRX 3.50%), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...

An exclusive excerpt from Every Screen On The Planet reveals how the social media app’s powerful recommendation engine was shaped by a bunch of ordinary, twentysomething curators—including a guy named ...